{"id":23789,"date":"2024-12-24T08:20:17","date_gmt":"2024-12-24T13:20:17","guid":{"rendered":"https:\/\/medicarereport.org\/?p=23789"},"modified":"2024-12-24T08:20:17","modified_gmt":"2024-12-24T13:20:17","slug":"fda-approves-glp-1-generic","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=23789","title":{"rendered":"FDA approves GLP-1 generic"},"content":{"rendered":"\n<p>(By Paige Twenter for <em>Becker&#8217;s Hospital Review<\/em>)<\/p>\n\n\n\n<p>On Dec. 23, the FDA approved Hikma Pharmaceuticals&#8217; liraglutide injection, a generic version of Novo Nordisk&#8217;s Victoza.<\/p>\n\n\n\n<p>The FDA first approved Victoza in 2010 for Type 2 diabetes, later expanding its use in 2019 as a pediatric, injectable treatment for patients 10 or older. Hikma&#8217;s generic includes similar warnings to the brand-name drug, such as risks of thyroid C-cell tumors, pancreatitis, hypoglycemia, kidney failure and acute gallbladder disease.  Continue reading <a href=\"https:\/\/www.beckershospitalreview.com\/glp-1s\/fda-approves-glp-1-generic.html\" data-type=\"link\" data-id=\"https:\/\/www.beckershospitalreview.com\/glp-1s\/fda-approves-glp-1-generic.html\">here&#8230;<\/a><\/p>\n\n\n\n<p><img loading=\"lazy\" decoding=\"async\" width=\"200\" height=\"65\" class=\"wp-image-7881\" style=\"width: 200px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/FDA-logo.jpg\" alt=\"\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/FDA-logo.jpg 322w, https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/FDA-logo-300x97.jpg 300w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Notice:<\/strong>\u00a0The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Paige Twenter for Becker&#8217;s Hospital Review) On Dec. 23, the FDA approved Hikma Pharmaceuticals&#8217; liraglutide injection, a generic version<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31,15],"tags":[76,429,1468,1651],"class_list":["post-23789","post","type-post","status-publish","format-standard","hentry","category-fda","category-part-dprescription-drugs","tag-fda","tag-generic-drugs","tag-glp-1-drugs","tag-victoza"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/23789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23789"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/23789\/revisions"}],"predecessor-version":[{"id":23790,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/23789\/revisions\/23790"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}